Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
Status:
Terminated
Trial end date:
2011-06-13
Target enrollment:
Participant gender:
Summary
This study of SCH 900776 (MK-8776) will evaluate its safety and tolerability when given in
combination with cytarabine to participants with acute leukemias. Participants in the
Dose-Escalation Part will be enrolled in cohorts that will receive sequentially higher doses
of MK-8776 in combination with standard doses of cytarabine. Only one combination treatment
cycle of approximately 4 to 6 weeks is anticipated, but participants may receive additional
cycles if clinically indicated after discussion between the Investigator and the Sponsor. The
recommended combination doses for a Phase 2 trial (RP2D) will be determined based on safety
and biological activity. Up to 10 to 15 additional participants will be studied at the
combination RP2D.